Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France
- Conditions
- COVID-19SARS (Severe Acute Respiratory Syndrome)
- Registration Number
- NCT04325646
- Lead Sponsor
- Institut Pasteur
- Brief Summary
On January 2020, the discovery of a new coronavirus (SARS-CoV-2) was officially announced by the Chinese health authorities and the World Health Organization (WHO). Its complete genome was sequenced by the laboratory of respiratory infection viruses at the Institut Pasteur on 29 January 2020 in France. This will allow the identification of antigenic structures involved in the immune response and the development of serological diagnostic tests.
Many questions are being asked about this new virus and the infection it causes, including questions about the percentage of asymptomatic and pauci-symptomatic forms. Serological studies can provide answers to these questions. There is no serological test for SARS-COV-2 yet, but the laboratory of respiratory infection viruses at the Institut Pasteur is working on its development.
This study proposes to carry out a collection of samples taken from subjects who travelled to China before the epidemic outbreak or suspected of being infected with SARS-CoV-2.
As soon as it is available, serology will be performed on the collected samples.
- Detailed Description
On January 2020, the discovery of a new coronavirus (SARS-CoV-2) was officially announced by the Chinese health authorities and the World Health Organization (WHO). This new virus is presented as the causative agent of pneumonias. Its complete genome was sequenced by the laboratory of respiratory infection viruses at the Institut Pasteur on 29 January 2020 in France. This will allow the identification of antigenic structures involved in the immune response and the development of serological diagnostic tests.
Many questions are being asked about this new virus and the infection it causes, including questions about the transition from animal to human occur, the beginning of viral circulation in humans, the period of contagiousness, the percentage of asymptomatic and pauci-symptomatic forms. Serological studies can provide answers to these questions. There is no serological test for SARS-COV-2 yet, but the laboratory of respiratory infection viruses at the Institut Pasteur is working on its development.
This study proposes to carry out a collection of samples taken from subjects who travelled to China before the epidemic outbreak or suspected of being infected with SARS-CoV-2.
As soon as it is available, serology will be performed on the collected samples.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 5000
- Affiliated with or benefiting from a Social Security system
- State of health compatible with a blood sample as defined in the protocol
- Person benefiting from a legal protection measure or unable to express informed consent to participation
- Have had an infectious episode and/or respiratory signs in the 14 days prior to the scheduled visit (CORSER 1 and 2a, 2b)
- Have been in contact with a confirmed case of SARS-CoV-2 infection within 14 days prior to the date of the visit.(CORSER 1 and 2a, 2b)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Presence of specific anti-SARS-CoV-2 antibodies in the different study groups. One year Description of the serological status of individuals by different detection tests
- Secondary Outcome Measures
Name Time Method Percentage of asymptomatic forms in individuals with anti-SARS-CoV-2 antibodies One year Proportion of asymptomatic subjects into seropositive population
Trial Locations
- Locations (21)
CHU Amiens-Picardie
🇫🇷Amiens, France
EHPAD Villa Concorde
🇫🇷Asnieres sur seine, France
CHU François Mitterand
🇫🇷Dijon, France
Centre Hospitalier Départemental de Vendée
🇫🇷La Roche-sur-Yon, France
CHU Limoges
🇫🇷Limoges, France
Hôpital de la Croix Rousse
🇫🇷Lyon, France
EHPAD Les Etangs
🇫🇷Mennecy, France
CHRU de Nancy
🇫🇷Nancy, France
Hôpitaux de Brabois
🇫🇷Nancy, France
CHR Orléans
🇫🇷Orléans, France
Scroll for more (11 remaining)CHU Amiens-Picardie🇫🇷Amiens, France